Beactica, BluSense Diagnostics and Optomed are the recipients of the Nordic Stars 2018 Award. The highly coveted award was presented to the winners from three Nordic countries at the conclusion of the Nordic Life Science Days (NLSDays) in Stockholm.
Growing numbers of one-on-one meetings and licensing opportunities year by year to a new all-time high underpin that the conference has become an established arena for high quality meetings between, companies, service providers, investors, research communities, and government and regulatory bodies.Approximately 1,280 delegates representing almost 800 companies from 40 countries joined the conference, thus confirming NLSDays’ role as the premier Nordic life sciences event.
Nordic Stars Award were introduced in 2013 in special recognition of life science companies in the Nordic region demonstrating outstanding innovation and entrepreneurial skills.
Björn Ursing, Chairman of the Nordic Stars Award commented:
– At SwedenBIO we are proud to present the three winners of the Nordic Stars Award 2018. Each of them constitutes an excellent example of how companies from the Nordics succeed in developing solutions that can contribute to better healthcare globally.
This year’s winners are:
Beactica has through a series of EU-grants and discovery collaborations with several global pharmaceutical companies proved to be a trusted partner in fragment-based lead generation. They have also used their proprietary methodologies to pursue their own drug discovery programs in oncology, attracting widespread interest from both investors and international pharma companies.
Blusense Diagnostics, Denmark
BluSense Diagnostics has developed an innovative point-of-care platform for accurate, portable and affordable infectious disease diagnostics. With a grant from European Innovation Council pilot (EIC pilot) and CE-marking for their reader and the first diagnostic test for acute dengue fever, they are now on the verge of a market launch, less than four years after incorporation.
Optomed has made fundus screening readily available and affordable for even small practices. Their devices in combination with AI-based software have enhanced detection of diabetic retinopathy. In addition to having a medical device filling specific needs, they have been successful in commercialization, making it available to patients worldwide.
Jonas Ekstrand, Director General of SwedenBIO also reflected on the highly successful two days:
– Nordic Life Science Days with its unique atmosphere, has once again proved to be the premium conference, partnering and networking event within life science in Northern Europe. Join us next year again when the conference takes place in Malmö in the south of Sweden.
Nordic Life Science Days 2018 in brief
Registered Delegates: 1280
Meeting requests: 14800
Meeting accepted: 2900
Partnering opportunities: 720
Malmö again next year
NLSDays will return to the south of Sweden in 2019. Join us next year in Malmö on September 10-12.
NLSDays is a SwedenBIO event, produced by Bionordic. NLSDays was founded in 2012 and has grown rapidly to become the largest Nordic partnering conference for the global life science industry.
Among the Big Pharma, investors and other major players registered for the meeting so far are AstraZeneca, MSD, Pfizer, Sanofi, SOBI, Boehringer Ingelheim, Roche, Bristol-Mayer Squibb, Bayer, Novo, Johnson & Johnson Innovation, GE Healthcare, DNB, Industrifonden, HealthCap, BioGeneration Ventures, Almi Invest, Gilde Healthcare, Gimv, Lundbeckfonden Ventures, Seventure Partners, IBM and IQVIA.
In addition to partnering, NLSDays also offers an exhibition and a seminar program. Speakers include senior representatives from the global life science companies, investors, and academic leaders who will all share their expertise and views for the future.
Läs mer på MyNewsDesk